Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
Get Alerts SRPT Hot Sheet
Rating Summary:
30 Buy, 9 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Oppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).
Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate and IP in commercialization of eteplirsen in the US. Additionally, it complicates enforcement of last year's "method of use" ruling in favor of BioMarin (note here). The decision is subject to appeal.
The firm Outperform price target of $76.00
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $48.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Super Micro Computer (SMCI) Falls 6%
- Piper Sandler Downgrades Magnolia Oil & Gas Corp. (MGY) to Neutral
- Ibotta (IBTA) starts trading at $118, price IPO at $88
Create E-mail Alert Related Categories
Analyst Comments, Litigation, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!